Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

(2016) Shuhang Wang et al.   Journal of Hematology & Oncology

190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)

(2016) K. Park et al.   Journal of Thoracic Oncology

Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters

(2016) Yun-Kai Zhang et al.   Scientific Reports

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

(2016) Leli Zeng et al.   Scientific Reports

Multidrug Resistance Proteins (MRPs) and Cancer Therapy

(2015) Yun-Kai Zhang et al.   AAPS Journal

Cyclometalated Ruthenium(II) Anthraquinone Complexes Exhibit Strong Anticancer Activity in Hypoxic Tumor Cells

(2015) Leli Zeng et al.   CHEMISTRY-A EUROPEAN JOURNAL

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy inEGFR-Mutant Lung Cancer: A Meta-Analysis

(2015) Chee Khoon Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Semi-synthetic ocotillol analogues as selective ABCB1-mediated drug resistance reversal agents

(2015) Yun-Kai Zhang et al.   Oncotarget

The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study

(2015) Rishil J. Kathawala et al.   Oncotarget

Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2

(2015) De-Shen Wang et al.   Oncotarget

Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1

(2014) Yi-Jun Wang et al.   BIOCHEMICAL PHARMACOLOGY

Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches

(2014) Qiong Wu et al.   CANCER LETTERS

Potential Protein Phosphatase 2A Agents from Traditional Chinese Medicine against Cancer

(2014) Kuan-Chung Chen et al.   Evidence-based Complementary and Alternative Medicine

MDR1 Synonymous Polymorphisms Alter Transporter Specificity and Protein Stability in a Stable Epithelial Monolayer

(2013) King Leung Fung et al.   CANCER RESEARCH

Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10)

(2013) WEN DENG et al.   ONCOLOGY REPORTS

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

(2013) A. O. Walter et al.   Cancer Discovery

Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance

(2012) Yue-Li Sun et al.   ANTI-CANCER DRUGS

GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance

(2012) Kamlesh Sodani et al.   BIOCHEMICAL PHARMACOLOGY

Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance

(2012) Suneet Shukla et al.   DRUG RESISTANCE UPDATES

Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib

(2011) Vince D. Cataldo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Prediction of Absolute Solvation Free Energies using Molecular Dynamics Free Energy Perturbation and the OPLS Force Field

(2010) Devleena Shivakumar et al.   Journal of Chemical Theory and Computation

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

(2009) C Hegedűs et al.   BRITISH JOURNAL OF PHARMACOLOGY

Development of inhibitors of ATP-binding cassette drug transporters – present status and challenges

(2008) Suneet Shukla et al.   Expert Opinion on Drug Metabolism & Toxicology